Showing results (861-870 of 2,411) with videos related to
Sort By:
Pageof 242
Journal of Medical Economics|May 20, 2009
Cost of care for new versus recurrent acute coronary syndrome patientsSharashchandra Shetty, Rachel Halpern, Patrick L McCollamJournal of Medical Economics|May 20, 2009
Clinical outcome of hypertension managementVivian Wy Lee, Tony Hw Chan, Tina Tl Ko, et al.Journal of Medical Economics|May 20, 2009
Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost studyMichel Burnier, Jacques A Douchamps, Ann Tanghe, et al.Journal of Medical Economics|July 2, 2009
Costs and quality of life effects of the first year of renal replacement therapy in one Finnish treatment centreTaru Hallinen, Erkki J O Soini, Janne A Martikainen, et al.Journal of Medical Economics|July 2, 2009
Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIsEric Q Wu, Paul E Greenberg, Elaine Yang, et al.Journal of Medical Economics|October 10, 2013
Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)Donna Lawrence, Michael Maschio, Kevin J Leahy, et al.Journal of Medical Economics|November 10, 2015
Using 'big data' to validate claims made in the pharmaceutical approval processThomas Wasser, Kevin Haynes, John Barron, et al.Journal of Medical Economics|May 28, 2010
Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasonsEric Q Wu, Rym Ben-Hamadi, Andrew P Yu, et al.Journal of Medical Economics|June 24, 2009
Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countriesManuela Helena Gschwend, Mark Aagren, William J ValentineJournal of Medical Economics|September 8, 2009
Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancerFabian T Camacho, Jun Wu, Wenhui Wei, et al.Pageof 242